Results 191 to 200 of about 222,027 (284)

D81 Mutants Reveal Hidden EF-Tu Diversity while Natural Sequences Preserve Aspartate. [PDF]

Comput Struct Biotechnol J
Johnson JL, Wang Y.
europepmc   +1 more source

Növényi RHO (ROP) GTP-áz aktivált kinázok azonosítása és jellemzése [PDF]

, 2009
Dorjgotov Dulguun
core  

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

Rab10 Promotes Atlastin-Mediated Endoplasmic Reticulum Membrane Fusion. [PDF]

FASEB J
Kim M, Na K, Kim H, Jang E, Yoon SY, Lee C, Jun Y.   +6 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

New Biochemical Insights into RIT GTPases Regulation and Membrane Interactions. [PDF]

Cells
Mirzaiebadizi A, Bazgir F, Mosaddeghzadeh N, Pudewell S, Kazemein Jasemi NS, Dvorsky R, Ahmadian MR.   +6 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment. [PDF]

Biomark Res
Jin S, Zhang Z, Liang F, Yang Y, Lu A, Liang C.   +5 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Tubulin flux at spastin-induced nanodamage sites regulates microtubule rescue frequency and EB1 lifetimes. [PDF]

Proc Natl Acad Sci U S A
Szczesna E, Spector JO, Sarbanes SL, Chen J, Szyk A, Roll-Mecak A.   +5 more
europepmc   +1 more source